Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1987-08-27
1990-02-13
Sneed, H. M. S.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514177, 514182, 514899, A61K 3156
Patent
active
049007343
ABSTRACT:
A pharmaceutical composition is provided for oral administration. The composition comprises estradiol dissolved in an oil vehicle containing a suspension of micronized progesterone. The oil vehicle is high in glycerides of polyunsaturated fatty acids. The estradiol and micronized progesterone contained in the oil are more readily absorbable in the blood stream and achieve enhanced estradiol and progesterone blood serum levels. The pharmaceutical composition according to the invention can be readily formulated into capsules and administered for the treatment of menopausal symptoms.
REFERENCES:
patent: 2675342 (1954-04-01), Lee et al.
patent: 3733407 (1973-05-01), Segre
patent: 3755575 (1973-08-01), Lerner
patent: 4150128 (1979-04-01), Jasionowski
patent: 4196188 (1980-04-01), Besins
patent: 4425339 (1984-01-01), Pitchford
Hargrove et al., "Absorption of Oral Progesterone Is Inhibited by Vehicle and Physical Characteristics", Abstract of 32nd Annual Meeting, Soc. Gyn. Invest. (3/85).
Swern, "Bailey's Ind. Oil & Fat Products", 3d ed. (Interscience, NY, 1965), pp. 207-212, 222 & 224-226.
Mattsson et al., "Evaluation of Continuous Oestroge-Progesteren Regime for Climacteric Complants", Maturitas, 4:95-102 (1982).
de Lignieres et al., "Differential Effects of Exogenous Oestradiol and Progesterone on Mood in Post-Menopausal Women", Maturitas, 4:67 (1982).
Staland, "Continuous Treatment with Natural Oestrogens and Progestogens, A Method to Avoid Endometrial Simulation", Maturitas 3:145-156 (1981).
Riis et al., "Post-Menopausal Bone Loss: Effects of Oestrogens and Progestogens, A Review", Maturitas, 8:267-274 (1986).
Judd, H. L., Cleary, R. E., Creasman, W. T., Figge, D. C., Kase, N., Rosewaks, Z., Tagatz, G.E., Estrogen Replacement Therapy, Obstet Gynecol, 1981;58:267-275.
Hammond, C. B., Maxson W. S., Current Status of Estrogen Therapy for Menopause, Fertil Steril, 1982;37:5-25.
Henderson, B. E., Ross, R. K., Paganini-Hill, A., Mack, T. M., Estrogen Use and Cardiovascular Disease, Am J Obstet Gynecol, 1986;154:1181-1186.
Henderson, B. E., Paganini-Hill, A., Ross, R. K., Estrogen Replacement Therapy and Protection from Acute Myocardial Infarction, Am J Obstet Gynecol, 1988;159:312-317.
Smith, D. C., Prentice, R., Thompson, D. J., Herrmann, W. L., Association of Exogenous Estrogen and Endometrial Carcinoma, N Engl J Med, 1975;293:1164-1167.
Ziel, H. K., Finkle, W. D,. Increased Risk of Endometrial Carcinoma Among Users of Conjugated Estrogens, N Engl J Med, 1975;293:1167-1170.
Whitehead, M, Lane, G, Siddle, N, Townsend, P, King, R., Avoidance of Endometrial Hyperstimulation in Estrogen-Treated Postmenopausal Women, Seminars in Reproductive Endocrinology, 1983;1:41-53.
Gambrell, R. D., Jr., Bagnell, C. A., Greenblatt, R. B., Role of Estrogens and Progesterone in the Etiology and Prevention of Endometrial Cancer: Review, Am J Obstet Gynecol, 1983;146:696-707.
Gambrell, R. D., Jr., Massey, F. M., Castaneda, T. A., Ugenas, A. J., Ricci, C. A., Wright, J. M., Use of the Progestogen Challenge Test to Reduce the Risk of Endometrial Cancer, Obstet Gynecol, 1980;55:732-738.
Holst, J., Cajander, S., von Schoultz, B., Endometrial Effects of a Continuous Percutaneous Oestrogen/Low Dose Progestogen Regimen for Climateric Complaints, Maturitas, 1987;9:63-67.
Lind, T., Cameron, E. C., Hunter, W. M., Leon, C., Moran, P. F., Oxley, A., Gerrard, J., Lind, U. C. G., A Prospective, Controlled Trial of Six Forms of Hormone Replacement Therapy Given to Postmenopausal Women, Br J Obstet Gynaecol, 1979;86(Suppl. 3):1-29.
Magos, A. L., Brincat, M., Studd, J. W. W., Wardle, P., Schlesinger, P., O'Dowd, T., Amenorrhea and Endometrial Atrophy with Continuous Oral Estrogen and Progestogen Therapy in Postmenopausal Women, Obstet Gynecol, 1985;65:496-499.
Staland, B., Continuous Treatment with Natural Oestrogens and Progestogens, A Method to Avoid Endometrial Stimulation, Maturitas, 1981;3:145-156.
Mattsson, L. A., Cullberg, G., Samsioe, G., Evaluation of a Continuous Oestrogen-Progestogen Regimen for Climacteric Complaints, Maturitas, 1982;4:95-102.
Mattsson, L. A., Cullberg, G., Samsioe, G., A Continuous Estrogen-Progestogen Regimen for Climacteric Complaints Effects on Lipid and Lipoprotein Metabolism, Acta Obstet Gynecol Scand, 1984;63:673-677.
Hellberg, D, Nilsson, S., Pilot Study to Evaluate a New Regimen to Treat Climacteric Complaints with Cyclic Combined Oestradiol Valerate/Medroxyprogesterone Acetate, Maturitas, 1987;9:103-107.
Weinstein, L., Efficacy of a Continuous Estrogen-Progestin Regimen in the Menopausal Patient, Obstet Gynecol, 1987;69:929-932.
Prough, S. G., Aksel, S., Wiebe, R. H., Shepherd, J., Continuous Estrogen/Progestin Therapy in Menopause, Am J Obstet Gynecol, 1987;157:1449-1453.
Luciano, A. A., Turksoy, R. N., Carleo, J., Hendrix, J. W., Clinical and Metabolic Responses of Menopausal Women to Sequential Versus Continuous Estrogen and Progestin Replacement Therapy, Obstet Gynecol, 1988;71:39-43.
Mashchak, C. A., Lobo, R. A., Dozono-Takano, R., Eggena, P., Nakamura, R. M., Brenner, P. F., Mishell, D. R., Comparison of Pharmacodynamic Properties of Various Estrogen Formulations, Am J Obstet Gynecol, 1982;144:511-518.
Gorrill, M. J., Marshall, J. R., Pharmacology of Estrogens and Estrogen-Induced Effects on Nonreproductive Organs and Systems, J Reprod Med Suppl, 1986;31:842-847.
Ottosson, U. B., Oral Progesterone and Estrogen/Progestogen Therapy, Effects of Natural and Synthetic Hormones on Subfractions of HDL Cholesterol and Liver Proteins, Acta Obstet Gynecol Scand [Suppl], 1984;127:1-37.
Fahraeus, L., Larsson-Cohn, U., Wallentin, L.. L-Norgestrel and Progesterone Have Different Influences on Plasma Lipoproteins, Europ J Clin Invest, 1983;13:447-453.
Fahraeus, L., Metabolic Consequences of Postmenopausal Estrogen and Progestogen Treatment, Acta Obstet Gynecol Scand Suppl, 1985;132:19-21.
Hirvonen, E., Malkonen, M., Manninen, V., Effects of Different Progestogens on Lipoproteins during Postmenopausal Replacement Therapy, N Eng J Med, 1981;304:560-563.
Larsson-Cohn, U., Fahraeus, L., Wallentin, L., Goran, Z., Lipoprotein Changes May Be Minimized by Proper Conmposition of a Combined Oral Contraceptive, Fertil Steril, 1981;35:172-179.
Padwick, M. L., Endacott, S. R. N., Whitehead, MI., Efficacy, Acceptability, and Metabolic Effects of Transdermal Estradiol in the Management of Postmenopausal Women, Am J Obstet Gynecol, 1985;152:1085-1091.
Powers, M. S., Schenkel, L., Darley, P. E., Good, W. R., Balestra, J. C., Place, V. A., Pharmacokinetics and Pharmacodynamics of Transdermal Dosage forms of 17B-Estradiol: Comparison with Conventional Oral Estrogens Used for Hormone Replacement, Am J Obstet Gynecol, 1985;152:1099-1106.
De Lignieres, B., Basdevant, A., Thomas, G., Thalabard, J. C., Mercier Bodard, C., Conard, J., Guyene, T. T., Mairon, N., Corvol, P., Guy Grand, B. et al., Biological Effects of Estradiol-17 beta in Postmenopausal Women: Oral Versus Percutaneous Administration, J Clin Endocrinol Metab, 1986; 62:536-541.
Stanczyk, F. Z., Shoupe, D., Nunez, V., Macias-Gonzales, P., Vijod, M. A., Lobo, R. A., A Randomized Comparison of Nonoral Estradiol Delivery in Postmenopausal Women, Am J Obstet Gynecol, 1988;159:1540-1546.
Rock, J. A., Wentz, A. C., Cole, K. A., Kimball, Jr,. A. W., Zacur, H. A., Early, S. A., Jones, G. S., Fetal Malformations Following Progesterone Therapy During Pregnancy: A Preliminary Report, Fertil Steril, 1985;44:17-19.
Wentz, A. C., Assessment of Estrogen and Progestin Therapy in Gynecology and Obstetrics, Clin Obstet Gynecol, 1977;20:461-482.
Arafat, E. S., Hargrove, J. T., Maxson, W. S., Desiderio, D. M., Wentz, A. C., Andersen, R. N., Sedative and Hypnotic Effects of Oral Administration of Micronized Progesterone May Be Mediated through Its Metabolites, Am J Obstet Gynecol, 1988;159:1203-1209.
Hargrove, J. T., Maxson, W. S., Wentz, A. C., Burnett, L. S., Menopausal Hormone Replacement Therapy with Continuous Oral Micronized Estradiol and Progesterone, Obstet Gynecol, 1989; (In Press).
Nichols, K. C., Schenkel, L., Benson, H., 17 beta-Estradiol for Postmenopausal Estr
Delk Joe H.
Hargrove Joel T.
Maxson Wayne S.
Saba James
Sneed H. M. S.
LandOfFree
Novel pharmaceutical composition containing estradiol and proges does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel pharmaceutical composition containing estradiol and proges, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel pharmaceutical composition containing estradiol and proges will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1168332